European Primary Care Cardiovascular Society
Reduction of antihypertensive medication in patients ≥80 years who were on ≥2 antihypertensive medication was noninferior to usual care with regard to SBP control at 12 weeks.
The P2Y12 inhibitor ticagrelor has now been approved by the FDA to reduce risk of first MI or stoke in high-risk coronary artery disease (CAD) patients.
This cross-trial analysis estimated that comprehensive disease-modifying pharmacological therapy in HFrEF patients reduces the hazard of CV death or hospital admission, compared with conventional therapy.
This analysis of the REGARDS study showed that AF patients without CV comorbidities had no increased risk of stroke compared to individuals without AF or CV comorbidities.
Out-of-hospital cardiac arrest during the inital phase of the COVID-19 outbreak was substantially increased in the Lombardia region in Italy compared to the same period in 2019. Baldi briefly presents the details and outcomes of a study.
A diagnostic model based on symptoms partly uncovered unrecognized AF, HF and CAD in participants from the Lifelines cohort study. This resulted in the development of an 11-item questionnaire for proactive screening.
A diagnostic model with data from the Lifelines cohort study improved early detection of unrecognized AF, HF and CAD in primary care. This translated into the development of a patient questionnaire.
Members of the Diabetes and Cardiovascular Disease EASD Study Group have published a perspective on issues of CV risk management in diabetes patients during the COVID-19 pandemic.
This systematic review and meta-analysis of 43 studies showed that the prescription prevalence in women was lower for aspirin, statins, and ACE inhibitors, but higher for diuretics, compared to men.
This study showed that the most frequent first manifestations of CV- and renal disease in T2D patients were HF and CKD, which were both associated with increased all-cause and CVD mortality risk.
A large Norwegian cohort study showed that drinking filtered coffee was associated with lower mortality than no coffee, while no association between coffee drinking and mortality was observed for those drinking unfiltered coffee.
Omecamtiv mecarbil, a cardiac myosin activator or cardiac myotrope, has been granted Fast Track designation by the FDA for treatment of HFrEF patients.
